Grassley: Mylan fleeced taxpayers $1.27 billion for EpiPen

Published



Taxpayers overpaid about $1.27 billion for the allergy drug EpiPen over a decade, far more than the $465 million the drug’s manufacturer previously reported.

Sen. Chuck Grassley, R-Iowa, said Medicaid gave EpiPen maker Mylan too much money from 2006 to 2016 because Mylan misclassified the allergy antidote. The Obama administration also failed to adequately fix the issue, he added.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.